(fifthQuint)A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma.

 This was a multicenter, randomized, double-blind, placebo- and active-controlled, Phase II, parallel-group study up to four weeks in duration.

 Seven days of QID (four times a day) single-blind, placebo administration (via metered dose inhaler (MDI)) was followed by 21 days of QID double-blind treatment.

 During the single-blind period, rescue medication consisted of racemic albuterol MDI (90 mcg per actuation) for all subjects.

 During the double-blind period, rescue medication consisted of double-blind levalbuterol MDI (45 mcg per actuation) for all subjects in the levalbuterol treatment groups or double-blind racemic albuterol MDI (90 mcg per actuation) for all subjects in the racemic albuterol and placebo treatment groups.

The study consisted of two periods, an optional follow-up visit, and a final telephone evaluation.

 This study was previously conducted by Sepracor Inc.

 In October 2009, Sepracor Inc.

 was acquired by Dainippon Sumitomo Pharma.

, and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

.

 A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma@highlight

Multicenter, randomized, double-blind, placebo- and active-controlled, Phase II, parallel-group study of up to four weeks in duration.

 The study consisted of a screening visit followed by a one-week single blind placebo period.

 At next visit, each subject was randomized to one of four treatment groups: 90 mcg levalbuterol, 180 mcg levalbuterol, 180 mcg racemic albuterol, or placebo.

 All study medication was administered as 2 actuations 4 times a day for 21 days.

